OUR MISSION: Help patients beat their cancer.
While tremendous advances have been made in the fight against cancer over the last two decades, it has not been enough. Too many people, young and old, still lose their battle with cancer, and those who survive often experience debilitating side effects from the drugs used to treat them. Our passion to make a positive difference in this regard is embodied in CT-262, the first in a new class of cancer-cell-selective (CCS) cytotoxic agents that has the potential to revolutionize the treatment of cancer.